Every Thursday we send out a curated newsletter on all things femtech and women’s health innovation. This is an excerpt from the latest edition. If you’d like to subscribe, you can do so at the bottom of this page.

MiMARK is developing in vitro diagnostic solutions for managing gynecological malignancies, with a particular emphasis on improving Endometrial Cancer diagnosis. This approach positions gynecological fluid as a key component in the next phase of liquid biopsy in gynecology.

Highlights

Endometrial cancer diagnostics company MiMARK secures €4.22M in seed funding.

Food-as-medicine platform startup Season acquires clinical assets from Wellory.

Pioneer Life Sciences Fundinvests in at-home fertility care company Béa Fertility.

GE launches MyBreastAi Suite, an AI-powered platform for mammography.

Fertility Mapper launches an NHS Fertility Funding Calculator to simplify treatment eligibility checks in the UK.

Kheiron‘s AI tool Mia increases breast cancer detection rate by 13% according to a new Nature study.

Ovia Healthunveils new fertility and family building benefits.

Vella Biosciences launches Research Consortium for the Scientific Study of Women’s Sexual Wellness.

In the Know

10 Non-Women’s Health Newsletters Everyone in Women’s Health Should Read (Femtech Insider)

How Plad Is Transforming Plantain Waste into Sustainable Menstrual Products (Femtech Insider)

The Creepy New Digital Afterlife Industry (IEEE Spectrum)

A fertility clinic destroyed my chance at motherhood (STAT News)

Why Do Beauty Brands Post About Politics (The Cut)

Climate change hits women’s health harder. Activists want leaders to address it at COP28 (AP News)

Racism, sexism and the crisis of Black women’s health (The Brink)